Lifecore Biomedical, Inc. (LFCR)

Lifecore Biomedical's stock has experienced several notable events over the past six months. In November 2025, the company reported its Q1 financial results, showing a loss but beating revenue estimates. Earlier, in August 2025, Lifecore's Q4 revenue surpassed expectations by 3%. The company also announced significant business developments, including signing a 10-year manufacturing deal to support a novel ophthalmic therapy in June 2025. Additionally, in June 2025, Lifecore received early full payment for a $17 million equipment sale. In December 2025, Lifecore signed a CDMO master services agreement with a new large global pharmaceutical customer. In January 2026, Lifecore announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company's stock has traded between a 52-week high of $8.98 and a low of $4.76. William Blair initiated coverage of Lifecore Biomedical with an "Outperform" recommendation in May 2025. The company has also completed a turnaround, transitioning to a pure-play US-based CDMO.

While specific traditional "demand seasonality" for Lifecore Biomedical's products and services is not explicitly detailed, there are strong indications of consistent and growing demand. The company has recently installed a state-of-the-art 5-head isolator filler, which is expected to roughly double its theoretical capacity. Despite currently operating at approximately 20% capacity utilization, the demand for this new capacity is already contracted, with management projecting revenues to rise significantly. This suggests a robust and contracted demand for its CDMO services and hyaluronic acid products. The company's expansion of infrastructure is also aimed at supporting growing demands from the global pharmaceutical market.

Lifecore Biomedical, Inc. is a CDMO specializing in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products. The company is a leading manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) used in injectable products for various medical conditions. Lifecore Biomedical also provides comprehensive product development services. The company operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic and Life Sciences Tools and Services industries. Lifecore Biomedical, Inc. was formerly known as Landec Corporation and officially changed its name in November 2022.

Lifecore Biomedical, Inc. serves customers in the United States, Belgium, the Netherlands, and internationally. The company's headquarters are located in Chaska, Minnesota. It operates three cGMP facilities and holds numerous certifications from regulators in Europe, Japan, and Brazil, as well as the International Organization for Standardization (ISO).

Lifecore Biomedical has focused on improving its operations, leading to reduced operational expenses and a more than 20% improvement in workforce productivity in manufacturing. The company's reputation has been positively impacted by its successful turnaround, transforming into a pure-play CDMO with strong growth prospects. Lifecore has also strengthened its reputation by signing multiple new programs with new customers and securing a significant CDMO master services agreement with a large global pharmaceutical company. The company's commitment to continuous improvement is further demonstrated by its plans to launch a new enterprise resource planning (ERP) system in Q1 2026.

Lifecore Biomedical, Inc. has a significant institutional ownership base, with 187 institutional owners and shareholders holding a total of 25,745,135 shares. Major institutional shareholders include Wynnefield Capital Inc., Legion Partners Asset Management, LLC, and Greenhaven Road Investment Management, L.P.. As of January 2025, institutional investors collectively owned 66.85% of the company, with mutual funds increasing their stake to 18.66% and insiders increasing their holdings to 3.47%. Individual investors held approximately 35% as of November 2024. Wynnefield Capital Inc. beneficially owned approximately 16.0% of the outstanding voting securities as of June 2024.